Exhibit 99.1 1 Ionis reports third quarter 2024 financial results WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinion Olezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in process On track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., November 6, 2024 – Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024. "Today, we stand ...

Ionis Pharmaceuticals (IONS) reported $134 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 6.9%. EPS of -$0.95 for the same period compares to -$1.03 a year ago.The reported revenue represents a surprise of +3.88% over the Zacks Consensus Estimate of $128.99 million. With the consensus EPS estimate being -$1.16, the EPS surprise was +18.10%.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compar ...

Ionis Pharmaceuticals (IONS) came out with a quarterly loss of $0.95 per share versus the Zacks Consensus Estimate of a loss of $1.16. This compares to loss of $1.03 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 18.10%. A quarter ago, it was expected that this drug discovery and development company would post a loss of $0.95 per share when it actually produced a loss of $0.45, delivering a surprise of 52.63%.Over the last fo ...

WAINUATM U.S. launch progressing well; approved in UK; positive CHMP opinionOlezarsen FCS PDUFA December 19, 2024 Donidalorsen HAE PDUFA August 21, 2025; EU regulatory submission in processOn track to achieve 2024 P&L financial guidance; increased 2024 cash guidance CARLSBAD, Calif., Nov. 6, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) (the "Company") today reported financial results for the third quarter of 2024."Today, we stand on the cusp of a new era for Ionis, with our first co-comme ...

Gain access to all of the market research and financial analytics used in the preparation of this article plus exclusive content and pharma, healthcare and biotech investment recommendations and research / analytics by subscribing to my channel, Haggerston BioHealth.I have been considering Ionis (NASDAQ: IONS ) as a potential "strong buy" opportunity for some time. I covered the Carlsbad, California-based developer of antisense, oligonucleotide therapeutics on multiple occasions, most recently in May, short ...

Webcast scheduled for Wednesday, November 6 at 11:30 a.m. Eastern TimeCARLSBAD, Calif., Oct. 23, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will host a live webcast on Wednesday, November 6th at 11:30 a.m. Eastern Time to discuss its third quarter 2024 financial results.The webcast may be accessed at https://ir.ionis.com/events-and-presentations/upcoming-events. A replay will be available for a limited time at the same address. About Ionis Pharmaceuticals, Inc.Fo ...

- Recommendation based on NEURO-TTRansform Phase 3 results showing WAINZUA demonstrated consistent and sustained benefit improving neuropathy impairment and quality of life versus placeboCARLSBAD, Calif., Oct. 21, 2024  /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that Ionis' and AstraZeneca's WAINZUA (eplontersen) has been recommended for approval by the Committee for Medicinal Products for Human Use (CHMP) in the European Union (EU) for the treatment of hereditary transthyret ...

– Data continue to demonstrate donidalorsen potential to deliver significant and sustained reductions in HAE attacks up to three years with monthly or every two-month dosing CARLSBAD, Calif., Oct. 3, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) announced today that it will present new three-year data from the Phase 2 open-label extension (OLE) study as well as additional results from the pivotal Phase 3 OASIS and OASISplus studies of donidalorsen, the company's investigational RNA-targete ...

Ionis Pharmaceuticals (IONS) announced that it is floating a secondary issue of 11.5 million shares of its common stock to the public at an issue price of $43.50 per share, amounting to nearly $500.3 million. The company also granted an option to underwriters of the issue to purchase an additional 1.725 million shares at the same price. The secondary offering is expected to close today. Buy Why Did IONS Stock Fall? Ionis' shares fell more than 12% on Tuesday after the announcement. Though the issue does not ...

CARLSBAD, Calif., Sept. 9, 2024 /PRNewswire/ -- Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced the pricing of an underwritten public offering of 11,500,000 shares of its common stock. The shares of common stock are being sold at a public offering price of $43.50 per share. The aggregate gross proceeds to Ionis from this offering are expected to be approximately $500.3 million, before deducting underwriting discounts and commissions and other estimated offering expenses payable by Ionis. Ionis ha ...